Question 1

What is Workopia?

Accepted Answer

Workopia is a free MCP server that provides AI-powered job search, resume building, and career advice. It works with Claude Desktop, ChatGPT, OpenClaw, Cursor, and any MCP-compatible AI assistant. Jobs are sourced directly from employer career pages, not scraped from job boards.

Question 2

How do I add Workopia to Claude Desktop?

Accepted Answer

Open Claude Desktop, go to Settings, then MCP Servers, and click Add Server. Enter the URL: https://workopia.io/api/mcp-jobs. No API key is needed. You can then search jobs, build resumes, and get career advice directly in your Claude conversations.

Question 3

Is Workopia free?

Accepted Answer

Yes, Workopia is completely free to use. No subscription, no payment, and no login required. Job search and career advice are unlimited. Resume generation is rate-limited to 20 per hour per user to prevent abuse.

Question 4

Where does Workopia get its job data?

Accepted Answer

Workopia sources jobs directly from employer career pages and ATS feeds such as Lever. It does not scrape LinkedIn, Indeed, SEEK, or other job boards. Every job listing links to the official employer posting.

Question 5

Does Workopia store my resume?

Accepted Answer

No. Resume content submitted via MCP is processed in-memory for PDF generation and discarded after the response. No copies are saved server-side. Workopia does not store conversation history, personal information, or user identity from MCP interactions.

Question 6

What AI platforms does Workopia work with?

Accepted Answer

Workopia works with any MCP-compatible AI client, including Claude Desktop, Claude Code, ChatGPT, OpenClaw (which supports Slack, Discord, WhatsApp, Telegram, and more), Cursor, Windsurf, and JetBrains IDEs. Just add the endpoint URL: https://workopia.io/api/mcp-jobs.

Headquarters	Miami, Florida, USA
Scale	2-10 employees
Stage	Early Stage
Founded	2010
Industry	Consulting, Advertising, Marketing, Real estate, Property management
Website	www.rpmmiamimetro.com
LinkedIn	linkedin.com/company/976877
Crunchbase	crunchbase.com/organization/real-property-management-e826
Twitter	—

Active jobs	849^[1]
Total jobs online	7,782^[2]
AI-related	24 (0.3%)^[3]

Date	Type	Headline
March 18, 2026	news	FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide The FDA has approved ICOTYDE™ (icotrokinra), an IL-23 receptor antagonist, for moderate-to-severe plaque psoriasis. This marks a significant advancement as it is the first and only targeted oral peptide for this condition, offering a new standard of care and treatment option for patients.
April 24, 2026	news	Johnson & Johnson Launches Landmark Head-to-Head Pulsed Field Ablation Trial in Persistent Atrial Fibrillation Johnson & Johnson has initiated a landmark head-to-head clinical trial (PERSIGMA) comparing its VARIPULSE Pro Platform with the FARAPULSE PFA platform for persistent atrial fibrillation. This study aims to provide crucial comparative evidence for electrophysiologists to make more informed treatment decisions.
April 24, 2026	news	Johnson & Johnson Enters Agreement to Acquire Atraverse Medical Johnson & Johnson is acquiring Atraverse Medical, a medical device company specializing in left-heart access and radiofrequency technology. This acquisition strengthens J&J's cardiac ablation solutions portfolio, enhancing its offerings for treating atrial fibrillation and other cardiac arrhythmias.
2026-07-08	product	Why Is Johnson & Johnson (NYSE:JNJ) Linked to S&P 500 Care?
2026-07-08	product	Dual-Energy EP Catheter Approval Could Be A Game Changer For Johnson & Johnson (JNJ)
2026-07-06	product	Johnson & Johnson, IBD stock of the day, in buy zone heading into earnings
2026-07-01	product	Johnson & Johnson (NYSE:JNJ) S&P 500 Boosts Global Healthcare Reach
2026-07-01	product	J&J's Innovative Medicine Business in Q2: Here's What to Watch

Headquarters	Thousand Oaks, California, USA
Parent	—
Founded	1980
Website	amgen.com

Active jobs	7^[1]
Total jobs online	1,809^[2]

Johnson & Johnson Innovative Medicine

Amgen